Metformin in Moderate and Severe Renal Failure (CKD 3-4): A Follow-up Study

• Status: Withdrawn
• Trial end date: 2017-06-07
• Target enrollment: 0
• Participant gender: All

Summary

To validate on the mid-term in moderate and severe renal failure (CKD 3-4) a nomogram to adapt a fixed metformin daily posology according to renal function on the basis of the first short-term study made by the investigators.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre Hospitalier Universitaire, Amiens
• Treatments: Metformin

Criteria

Inclusion Criteria:

• Type 2 diabetes patients with stable CKD stages 3A, 3B and 4 aged between 18 and 80 years requiring metformin (and any other antidiabetic treatment)

Exclusion Criteria:

• Hyperlactatemia (> 2.5 mmol/L)

• No creatinine levels available since 3 months

• Severe hepatic insufficiency

• No liver function parameters available

• Need of investigation with iodized contrast media

• Hypersensitivity to metformin